Compare RANI & WEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RANI | WEA |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.9M | 125.4M |
| IPO Year | 2021 | N/A |
| Metric | RANI | WEA |
|---|---|---|
| Price | $0.86 | $10.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 24.4K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.87% |
| EPS Growth | ★ 57.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,633,000.00 | N/A |
| Revenue This Year | $274.77 | N/A |
| Revenue Next Year | $79.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 58.85 | N/A |
| 52 Week Low | $0.44 | $10.30 |
| 52 Week High | $3.87 | $11.44 |
| Indicator | RANI | WEA |
|---|---|---|
| Relative Strength Index (RSI) | 58.60 | 47.93 |
| Support Level | $0.86 | $10.46 |
| Resistance Level | $0.95 | $10.72 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 65.07 | 62.50 |
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The fund invests in bonds of companies operating in different sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.